References

lvrach

Лечащий Врач

Lechaschi Vrach

1560-51752687-1181

lvrach-373

Research Article

Статьи

Поражение периферической нервной системы, ассоциированное с приемом лекарственных средств

Affection of peripheral nervous system associated with drug taking

Ситкали

И. В.

Sitkali

I. V.

kolokolov@inbox.ru

Чиричкин

А. С.

Chirichkin

A. S.

noemail@neicon.ru

Колоколов

О. В.

Kolokolov

O. V.

noemail@neicon.ru

ФГБОУ ВО СГМУ им. В. И. Разумовского МЗ РФRussian Federation

2019

23062021

051919

2021

Ситкали И.В., Чиричкин А.С., Колоколов О.В.

Sitkali I.V., Chirichkin A.S., Kolokolov O.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.lvrach.ru/jour/article/view/373

Представлены современные сведения о патогенезе лекарственных полиневропатий, обсуждены основные этиологические факторы, вопросы терапии. Приведены данные о распространенности, клинико-нейрофизиологических особенностях полиневропатий, индуцированных химиотерапией.

The modern data on pathogenesis of drug polyneuropathies were presented, main etiological factors and therapeutic issues were discussed. The data on prevalence, clinical and neurophysiological features induced by chemotherapy were given.

АмиодаронНейротоксичностьПолинейропатияПсихоневрологияСимпозиумСтатиныТерапияХимиотерапия

polyneuropathyneurotoxicitychemotherapystatinsamiodaronisoniasid

References1

Hanewinckel R., Drenthen J., van Oijen M. et al. Prevalence of polyneuropathy in the general middle-aged and elderly population // Neurology. 2016; 87: 1892-1898.

Lubec D., M?llbacher W., Finsterer J. Diagnostic work-up in peripheral neuropathy: an analysis of 171 cases // Postgrad Med J. 1999, Dec, 75 (890): 723-727.

Azhary H., Farooq M. U., Bhanushali M. et al. Peripheral neuropathy: differential diagnosis and management // Am Fam Physician. 2010; 81 (7): 887-892.

Mark R. J., Ivan Urits, John Wolf et al. Drug-Induced Peripheral Neuropathy, A Narrative Review // Current Clinical Pharmacology. 2019; 14 (1): 1574-8847.

Green S., Holton A. Drug-induced peripheral neuropathy // Adverse Drug React Bull. 2016, Oct; 300 (1): 1159-1162.

Ma J., Kavelaars A., Dougherty P. M. et al. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source // Cancer. Wiley-Blackwell. 2018, Jun; 124 (11): 2289-2298.

Windebank A. J., Grisold W. Chemotherapy-induced neuropathy // J Peripher Nerv Syst 2008; 13: 27-46.

Ferrier J., Pereira V., Busserolles J. et al. Emerging trends in understanding chemotherapy-induced peripheral neuropathy // Curr. Pain Headache Rep. 2013; 17: 364.

Cashman C. R., H?ke A. Mechanisms of distal axonal degeneration in peripheral neuropathies // Neurosci Lett. Elsevier. 2015, Jun; 596: 33-50.

McDonald E. S., Randon K. R., Knight A. et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity // Neurobiol Dis. Academic Press. 2005, Mar, 18 (2): 305-313.

Kidd J. F., Pilkington M. F., Schell M. J. et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore // J Biol Chem. American Society for Biochemistry and Molecular Biology. 2002, Feb; 277 (8): 6504-6510.

Meregalli C., Chiorazzi A., Carozzi V. A. et al. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomibinduced peripheral neuropathy // Cell Cycle. 2014, Feb; 13 (4): 612-621.

Adelsberger H., Quasthoff S., Grosskreutz J. et al. The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons // Eur J Pharmacol. 2000 Oct; 406 (1): 25-32.

Raeder E. A., Podrid P. J., Lown B. Side effects and complications of amiodarone therapy // Am Heart J. 1985; 109: 975-983.

Charness M. E., Morady F., Scheinman M. M. Frequent neurologictoxicity associated with amiodarone therapy // Neurology. 1984; 34: 669-671.

Vilholm O. J., Christensen A. A., Zedan A. H. et al. Drug-Induced Peripheral Neuropathy // Basic Clin Pharmacol Toxicol. 2014; 115 (2): 185-192.

Wu C., Tcherny-Lessenot S., Dai W. et al. Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics // Clin Ther. 2018, Mar; 40 (3): 450-455.

Corrao G., Zambon A., Bertu L. et al. Lipid-lowering drugs prescription and the risk of peripheral neu-ropathy an exploratory case-control study using automated databas-es // J Epidemiol Community Health. 2004; 58: 1047-1051.

Gaist D., Jeppesen U., Andersen M. et al. Statins and risk of polyneuropathy // Neurology. 2002; 58: 1333-1337.

Svendsen T de K., N?rregaard Hansen P., Garc?a Rodr?guez L. A. et al. Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013 // Br J Clin Pharmacol. Wiley-Blackwell. 2017, Sep; 83 (9): 2087-2095.

Seretny M., Currie G. L., Sena E. S. et al. Incidence, prevalence, andpredictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis // Pain. 2014; 155: 2461-2470.

Green E., Sargent D. J., Goldberg L. M. et al. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 / GI Cancer Symposium. Hollywood, FL, 2005. Р. 27-29.

Windebank A. J., Grisold W. Chemotherapy-induced neuropathy // J Peripher Nerv Syst. 2008; 13 (1): 27-46.

Grisold W., Cavaletti G., Windebank A. J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention // Neuro-Oncology. 2012; 14 (4): 54.

Семенова А. И. Кардио- и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение) // Практич. онкология. 2009; 10 (3): 168-176.

Gregg R. V., Molepo J. M., Monpetit V. J. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurologic tissues, and morphologic evidence of toxicity // J. Clin. Oncol. 1992; 10: 795-803.

Brewer J. R., Morrison G., Dolan M. E. et al. Chemotherapyinduced peripheral neuropathy: Current status and progress // Gynecol Oncol. Academic Press. 2016, Jan; 140 (1): 176-183.

Sandler S. G., Tobin W., Henderson E. S. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients // Neurology. 1969; 19: 367-374.

Casey E. B., Jellife A. M., Le Quesne P. M. et al. Vincristineneuropathy. Clinical and electrophysiological observations // Brain1. 973; 96: 69-86.

Staff N. P., Grisold A., Grisold W. et al. Chemotherapyinduced peripheral neuropathy: A current review // Ann Neurol. NIH Public Access. 2017, Jun; 81 (6): 772-781.

Fujita S., Hirota T., Sakiyama R. et al. Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy // J Neurochem. 2019, Feb; 148 (3): 373-385.

Delforge M., Blad? J., Dimopoulos M. A. et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues // Lancet Oncol. 2010, Nov; 11 (11): 1086-1095.

Luo J., Gagne J. J., Landon J. et al. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study // Eur J Cancer. 2017, Jan; 70: 22-33.

Ludwig H., Delforge M., Facon T. et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia // Nature Publishing Group. 2018, May; 32 (7): 1542.

Yin Y., Qi X., Qiao Y. et al. The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy // Curr Cancer Drug Targets. 2019; 19 (1): 50-64.

Vahdat L. T., Thomas E. S., Roch? H. H. et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials // Support Care Cancer. Springer-Verlag; 2012; 20 (11): 2661-2668.

Kim P. G., Bridgham K., Chen E. C. et al. Incident adverse events following therapy for acute promyelocytic leukemia // Leuk Res reports. 2018; 9: 79-83.

Kuhn M., Nabergoj M., Sammartin K. et al. Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report // Mediterr J Hematol Infect Dis. 2016; 8 (1).

Van Der Watt J. J.,. Harrison T. B., Benatar M. et al. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: A systematic review // International Journal of Tuberculosis and Lung Disease. 2011; 15: 722-728.

Yoon Y. H., Jung K. H., Sadun A. A. et al. EthambutolInduced Vacuolar Changes and Neuronal Loss in Rat Retinal Cell Culture: Mediation by Endogenous Zinc // Toxicol Appl Pharmacol. Academic Press. 2000, Jan; 162 (2): 107-114.

Koul P. A. Ocular toxicity with ethambutol therapy: Timely recaution // Lung India. Wolters Kluwer - Medknow Publications. 2015; 32 (1): 1-3.

Duffy L. F., Daum F., Fisher S. E. et al. Peripheral neuropathy in Crohn’s disease patients treated with metronidazole // Gastroenterology. 1985, Mar; 88 (3): 681-684.

Shin I-S. J., Baer A. N., Kwon H. J. et al. Guillain-Barr? and Miller Fisher syndromes occurring with tumor necrosis factor ? antagonist therapy // Arthritis Rheum. 2006, May; 54 (5): 1429-1434.

Marzo M. E., Tintor? M., Fabregues O. et al. Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha // J Neurol Neurosurg Psychiatry. BMJ Publishing Group Ltd. 1998, Oct; 65 (4): 604.

Kato-Motozaki Y., Komai K., Takahashi K. et al. Polyethylene Glycol Interferon ?-2b-induced Immune-mediated Polyradiculoneuropathy // Internal medicine (Tokyo, Japan). 48. 569-572.

Cr?ange A., Lefaucheur J. P. Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis // J Neurol Neurosurg Psychiatry. BMJ Publishing Group Ltd. 2000, Mar; 68 (3): 395.

Bharadwaj A., Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology // Oxford University Press. 2004, May; 43 (7): 934-934.

Cossu G., Ceravolo R., Zibetti M. et al. Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition // Parkinsonism Relat Disord. 2016, Jun; 27: 81-84.

Toth C., Breithaupt K., Ge S. et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease // Ann Neurol. 2010. 68 (1): 28-36.

Merola A. Romagnolo A., Zibetti M. et al. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: A long-term prospective assessment // Eur J Neurol. 2016; 23 (3): 501-509.

Ceravolo R., Cossu G., Bandettini di Poggio M. et al. Neuropathy and levodopa in Parkinson’s disease: Evidence from a multicenter study // Mov Disord. 2013. 28: 1391-1397.

Boussaud V., Daudet N., Billaud E. M. et al. Neuromuscular Painful Disorders: a Rare Side Effect of Voriconazole in Lung Transplant Patients Under Tacrolimus // J Hear Lung Transplant. 2008. 27; 229-232.

Baxter C. G., Marshall A., Roberts M. et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy // J Antimicrob Chemother. 2011. 66 (9): 2136-2139.

Dworkin R. H., Corbin A. E., Young J. P. et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial // Neurology. 2003. 60 (8): 1274-1283.

Nishikawa N., Nomoto M. Management of neuropathic pain // J Gen Fam Med. Wiley-Blackwell. 2017; 18 (2): 56-60.

Dworkin R. H., O’Connor A. B., Kent J. et al. Interventional management of neuropathic pain: NeuP-SIG recommendations // Pain. NIH Public Access. 2015. 154 (11): 2249-2261.

Head K. A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies // Altern Med Rev. 2006; 11 (4): 294-329.

Fonseca V. A., Lavery L. A., Thethi T. K. et al. Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial // Am J Med. 2013; 126 (2): 141-149.

Tsubaki M., Takeda T., Matsumoto M. et al. Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway // Tumor Biol. 2018; 40 (10): 1010428318808670.

The authors declare that there are no conflicts of interest present.